Becton Dickinson and Co vs National Beverage Corp. — how do they compare? Becton Dickinson and Co trades at $182.32 (market cap $49.41B), while National Beverage Corp. trades at $30.74 (market cap $2.89B). The key difference: Becton Dickinson and Co is far larger — about 17.1× National Beverage Corp.'s market cap, and Becton Dickinson and Co pays a 2.32% dividend while National Beverage Corp. pays none. Which is the better fit depends on your goals.
| BDX | FIZZ | |
|---|---|---|
Market Cap | $49.41B | $2.89B |
Sector | Health | Consumer Cyclical |
52-Week High | $185.39 | $46.75 |
52-Week Low | $138.62 | $30.53 |
Enterprise Value | $65.51B | $2.60B |
Dividend Yield | 2.32% | — |
Signals from Pluang's Aura AI — not financial advice
BDX trades at $180.64, up 0.56% today, near its consensus price target of $183. The stock shows bullish technical signals with strong moving averages and recent earnings beats in Q2 2026. Revenue growth is steady, with Q3 2026 reaching $5 billion, though margins face pressure from tariffs. The company maintains a Dividend Aristocrat status with consistent payouts.
Outlook is cautiously optimistic with analyst consensus leaning buy, but risks include margin compression and debt levels. The stock offers stability through dividends and sector resilience, yet investors should monitor earnings sustainability and competitive threats in the medical technology space.
FIZZ trades at $30.60, down 1.42% on the day, with bearish technical signals dominating. The stock shows mixed fundamentals with strong profitability metrics including 37% gross margins and 34% ROE, but faces growth challenges as revenue has stagnated around $1.2B annually. Recent earnings have missed expectations in three of the last four quarters, while the company maintains dividend payments with a recent $3.25 special dividend declaration.
The outlook remains cautious given stalled revenue growth and bearish analyst sentiment with 50% sell ratings. While valuation appears reasonable at 15.7x P/E, competitive pressures in the sparkling water market and declining LaCroix volumes present significant headwinds. The stock's current technical weakness near support levels suggests continued pressure unless fundamental catalysts emerge.
Trailing returns across standard periods
Latest headlines on both assets
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →